Skip to main content
The BMJ logoLink to The BMJ
letter
. 2006 Mar 4;332(7540):550. doi: 10.1136/bmj.332.7540.550

Does melatonin improve sleep?

Efficacy of melatonin

Josephine Arendt 1
PMCID: PMC1388143  PMID: 16513724

Editor—Buscemi et al in their meta-analysis report that melatonin is ineffective in treating secondary sleep disorders or sleep disorders accompanying sleep restriction such as jet lag or shift work.1 The published reports in this domain certainly show some inconsistency, and now there is inconsistency in the meta-analyses.2 Numerous published studies, mostly with a positive result, have not been included, even the first controlled jet lag trial, published in the BMJ.3

Buscemi et al may have done a disservice to people who do benefit from melatonin and may in consequence be denied access (in the United Kingdom) to this prescription-only medication. For example, the authors do not mention the importance of melatonin in blind sleep disorder and delayed sleep phase syndrome. Some of the data have appeared previously in a report from the Agency for Healthcare Research and Quality,3 where benefits for delayed sleep phase syndrome were identified.4

Figure 1.

Figure 1

Successful use of melatonin to counter the effects of a change in time zones or shift work requires correct timing of treatment relative to internal circadian rhythms. Incorrect timing can lead to undesirable effects. It is difficult to time melatonin correctly in field studies. Uncontrolled exposure to natural light (which shifts internal timing), individual differences, and unscheduled sleep times all contribute to the problems. If a reliable and rapid method for assessing the timing of the human internal clock (and hence the timing of treatment) were available no doubt the efficacy of melatonin would be enhanced.

A more helpful approach to assessing the usefulness of melatonin would be to evaluate those few studies where circadian timing was either measured or accurately predicted before treatment.

Competing interests: JA is a member of the sleep advisory board, Alliance Pharmaceuticals.

References

  • 1.Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold L, Hartling L, et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006;332: 385-93. (18 February.) [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, Ford I. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005;9: 41-50. [DOI] [PubMed] [Google Scholar]
  • 3.Arendt J, Aldhous M, Marks V. Alleviation of jet-lag by melatonin: preliminary results of controlled double-blind trial. BMJ 1986;292: 1170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Agency for Healthcare Research and Quality. AHRQ issues new report on the safety and effectiveness of melatonin supplements. Press release, 8 December 2004. AHRQ. Rockville, MD, USA. www.ahrq.gov/news/press/pr2004/melatnpr.htm

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES